Evidence map›Paper›PMID 41122326›Full record

ArticleActa naturae

The Design, Synthesis, and Evaluation of the Biological Activity of Hydroxamic Derivatives of Sorafenib.

A A Kleymenova, I A Abramov, Ya V Tkachev, P S Galeeva, V A Kleymenova, N F Zakirova, S N Kochetkov, M V Kozlov

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta naturae. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A A KleymenovaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
I A AbramovEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
Ya V TkachevEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
P S GaleevaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
V A KleymenovaSechenov First Moscow State Medical University (Sechenov University), Moscow, 119991 Russia.
N F ZakirovaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
S N KochetkovEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
M V KozlovEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sorafenib is a multiple tyrosine kinase inhibitor that is used in the treatment of liver and renal cancers. We synthesized the hydroxamic derivatives of sorafenib bearing the pharmacophore elements of zinc-dependent histone deacetylase inhibitors. We uncovered that suppression of cancer cell proliferation by the synthesized hybrid inhibitors critically depends on the structure of the "deacetylase" element.

Indexed as

antiproliferative activityhybrid inhibitorsprotein tyrosine kinasessorafenibvorinostatzinc-dependent histone deacetylases

Identifiers

PMID41122326
PMCPMC12536992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.